|
2021 Journal Article PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics eraRyder, Simon J., Love, Amanda J., Duncan, Emma L. and Pattison, David A. (2021). PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clinical Endocrinology, 95 (1), 13-28. doi: 10.1111/cen.14375 |
|
2021 Journal Article [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A. ... TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397 (10276), 797-804. doi: 10.1016/S0140-6736(21)00237-3 |
|
2021 Journal Article Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluationArnfield, Evyn G., Thomas, Paul A., Roberts, Matthew J., Pelecanos, Anita M., Ramsay, Stuart C., Lin, Charles Y., Latter, Melissa J., Garcia, Peter L. and Pattison, David A. (2021). Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 48 (13), 4495-4507. doi: 10.1007/s00259-021-05456-3 |
|
2019 Journal Article Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocolIravani, Amir, Solomon, Benjamin, Pattison, David A., Jackson, Price, Ravi Kumar, Aravind, Kong, Grace, Hofman, Michael S., Akhurst, Tim and Hicks, Rodney J. (2019). Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid, 29 (11), 1634-1645. doi: 10.1089/thy.2019.0143 |
|
2019 Journal Article Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CTPattison, David A., MacFarlane, Lisa L., Callahan, Jason, Kane, Emma L., Akhurst, Timothy and Hicks, Rodney J. (2019). Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. EJNMMI Research, 9 (1) 15, 15. doi: 10.1186/s13550-019-0480-2 |
|
2017 Journal Article 18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual InterpretationPattison, David A., Bozin, Michael, Gorelik, Alexandra, Hofman, Michael S., Hicks, Rodney J. and Skandarajah, Anita (2017). 18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. Journal of Nuclear Medicine, 59 (5), 749-755. doi: 10.2967/jnumed.117.198085 |
|
2017 Journal Article Molecular imaging in the investigation of hypoglycaemic syndromes and their managementPattison, David A. and Hicks, Rodney J. (2017). Molecular imaging in the investigation of hypoglycaemic syndromes and their management. Endocrine-Related Cancer, 24 (6), R203-R221. doi: 10.1530/erc-17-0005 |
|
2026 Journal Article Primary hyperparathyroidism in adults: Recent developments in diagnosis and managementWootton, Elizabeth, De Sousa, Sunita M. C., Prince, Richard L., McLeod, Donald S. A., Pattison, David A. and Grossmann, Mathis (2026). Primary hyperparathyroidism in adults: Recent developments in diagnosis and management. Medical Journal of Australia, 224 (5) e70194, 1-11. doi: 10.5694/mja2.70194 |
|
2026 Journal Article [177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trialChan, David L, Sjoquist, Katrin Marie, Ransom, David Turner, Wyld, David, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A, Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, John, Leyden, Simone, Zalcberg, John Raymond, Turner, J. Harvey and Pavlakis, Nick (2026). [177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial. European Journal of Cancer, 241 116781, 116781. doi: 10.1016/j.ejca.2026.116781 |
|
2026 Journal Article Predictive value of early PSMA upregulation for the response to enzalutamide ± <SUP>177</SUP>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialEmmett, Louise, Swiha, Mina, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn, Goh, Jeffrey, Pattison, David, Pathmanandavel, Sarennya, Hope, Thomas, Ayati, Narjess, Hofman, Michael, Sandhu, Shahneen, Niu, Claire, Martin, Andrew, Thomas, Hayley, Stockler, Martin and Davis, Ian (2026). Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. Nature Cancer, 7 (4), 622-630. doi: 10.1038/s43018-026-01140-3 |
|
2026 Journal Article <sup>177</sup> Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerAyati, Narjess, Papa, Nathan, Crumbaker, Megan, Subramaniam, Shalini, Joshua, Anthony M., Alipour, Ramin, Iravani, Amir, Askari, Emran, Khan, Sobia, Yadav, Surekha, Eiber, Matthias, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Nguyen, Andrew, Hofman, Michael S., Sandhu, Shahneen, Hioki, Takanori, van Oorschodt, Julian C. J., Devitt, Katrina, Willowson, Kathy, Sharma, Shikha, Stancu, Alexandru, Chauvie, Stephane ... on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group (2026). 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology, 319 (1) e252672, e252672. doi: 10.1148/radiol.252672 |
|
2026 Journal Article Prognostic value of interim PSMA-PET total tumor volume for overall survival within ENZA-p, a randomized phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)Emmett, Louise, Papa, Nathan, Sartor, Oliver, Morris, Michael J., Subramaniam, Shalini, Crumbaker, Megan, Ayati, Narjess, Chen, Jeffrey, Herrmann, Ken, Gafita, Andrei, Swiha, Mina, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Ho, Bao, Khan, Sobia, Tan, Thean Hsiang, Bills, Madison, Nguyen, Andrew, Thein, Thida, Sidhom, George, Wong, Keith, Martin, Andrew James, Hofman, Michael S., Sandhu, Shahneen ... Davis, Ian D. (2026). Prognostic value of interim PSMA-PET total tumor volume for overall survival within ENZA-p, a randomized phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901). European Urology. doi: 10.1016/j.eururo.2026.03.026 |
|
2026 Journal Article Phase 2 expansion study of <sup>212</sup> Pb-ADVC001 in metastatic prostate cancer: The TheraPb trialHansen, Aaron Richard, Goh, Jeffrey C., Pattison, David A., Ngai, Stanley, Gan, Chun Loo Loo, Katchel, Loren, Brady, Jasmine, Kuchel, Anna, Latter, Melissa, Mason, Robert, Santoro, Paola, Crumbaker, Megan, Baronet, Meghan C., Grace, Reilly, Brilhante, Joana, Kryza, Thomas, Kuan, Kevin, Wiegert, Erol, Karmann, Anna and Wyld, David (2026). Phase 2 expansion study of 212 Pb-ADVC001 in metastatic prostate cancer: The TheraPb trial. Journal of Clinical Oncology, 44 (7_suppl). doi: 10.1200/jco.2026.44.7_suppl.tps280 |
|
2026 Journal Article Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and novel 212Pb PET Clinical ImagingHansen, Aaron R, Ngai, Stanley, Goh, Jeffrey C, Wyld, David, Gan, Chun Loo, Katchel, Loren, O'Mahoney, Eoin, Griffiths, Matthew R, Brady, Jasmine, Kuchel, Anna, Latter, Melissa, Mason, Robert, Santoro, Paola, Crumbaker, Megan, Baronet, Meghan C, Grace, Reilly, Brilhante, Joana, Rose, Stephen, Kryza, Thomas, Kuan, Kevin, Wiegert, Erol, Karmann, Anna and Pattison, David A (2026). Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and novel 212Pb PET Clinical Imaging. Journal of Medical Imaging and Radiation Sciences, 57 (2) 102292, 102292. doi: 10.1016/j.jmir.2026.102292 |
|
2026 Journal Article Assessing Correlation of Quantitative Technetium-99m Sestamibi Uptake in Thyroid Scintigraphy With Treatment Duration in Amiodarone-Induced ThyrotoxicosisWang, Ray, Better, Nathan, Sivaratnam, Dinesh, Westcott, James, Forehan, Simon, Pattison, David A. and Fourlanos, Spiros (2026). Assessing Correlation of Quantitative Technetium-99m Sestamibi Uptake in Thyroid Scintigraphy With Treatment Duration in Amiodarone-Induced Thyrotoxicosis. Journal of Medical Imaging and Radiation Oncology 1754-9485.70120. doi: 10.1111/1754-9485.70120 |
|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D, Stockler, Martin R and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2025 Journal Article A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancerRoberts, Matthew J., Roberts, Natasha A., Pelecanos, Anita, Yaxley, John W., Harley, Simon J. D., Siriwardana, Amila R., Cullen, Karla, Prior, Marita, Lindsay, Karen, Vela, Ian, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David A. (2025). A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer. EJNMMI Research, 15 (1) 92, 1-10. doi: 10.1186/s13550-025-01265-z |
|
2025 Journal Article Peptide receptor radionuclide therapy in malignant insulinomaPattison, David A., Kong, Grace, Akhurst, Timothy, Burge, Matthew, Chiang, Cherie, Hofman, Michael S., Hung, Te-Jui, Love, Amanda, Michael, Michael, Okano, Satomi, Ravi Kumar, Aravind S., Sachithanandan, Nirupa, Wyld, David and Hicks, Rodney J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine-Related Cancer, 32 (6) e250018, 6. doi: 10.1530/erc-25-0018 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... on behalf of the TheraP Investigators and the ANZUP Cancer Trials Group (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 2025 (8), 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST studyFielding, David, Sidhu, Calvin, Alkhater, Mahmoud, Alawami, Moayed, Kops, Stephan E. P., van der Heijden, Erik H. F. M., Bashirzadeh, Farzad, Windsor, Morgan, Nixon, Elizabeth, Son, Jung Hwa, Ananda Setty, Niranjan, Pattison, David A., Fong, William, Bhatt, Manoj, Dhiantravan, Nattakorn, Ramsay, Stuart, Boots, Robert, Putt, Michael, Pratt, Gary, Bettington, Catherine, Francis, Roslyn, Thomas, Paul, Steinke, Karin and Thomas, Rajesh (2025). Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study. BMJ Open Respiratory Research, 12 (1) e002553, 1-10. doi: 10.1136/bmjresp-2024-002553 |
